Status:
COMPLETED
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
Lead Sponsor:
AstraZeneca
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The primary objective is to describe the quality of life of long-term survivors who are not terminated from the EAP.
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study specific procedures.
- Participated in the Iressa EAP in China.
- Diagnosed as NSCLC.
- Patients who started EAP at least 3 years before this study initiated and have not yet terminated from the EAP (active long-term survivors).
- Patients who consent to provide blood sample and available archival tumour tissue sample for EGFR gene testing (provision of tumour tissue sample is optional).
Exclusion
- Patients who disagree to participate this study.
- Patients in whose medical objection was recorded to use the existing data from medical practice for scientific research.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT01000740
Start Date
August 1 2009
End Date
April 1 2010
Last Update
May 21 2010
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, Beijing Municipality, China
2
Research Site
Guangzhou, Guangdong, China
3
Research Site
Wuhan, Hubei, China
4
Research Site
Nanjing, Jiangsu, China